• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Bionano Announces CFO Transition and Appointment of Gülsen Kama as Chief Financial Officer

    8/14/23 8:00:00 AM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $BNGO alert in real time by email

    SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that Gülsen Kama will serve as its next Chief Financial Officer (CFO), effective September 11, 2023. Christopher Stewart, who held the position of CFO since September 2020, will stay on during the transition and then move into an advisory role.

    Ms. Kama has an extensive background in business planning and execution, especially in operating environments that demand rigorous management of expenses to enable profitable growth. She was most recently Chief Financial Officer at Northern Data AG, where she created and implemented a global finance organization to enable strong growth. Prior to Northern Data AG, Ms. Kama was Chief Financial Officer, East Region and Healthcare IT at Quest Diagnostics, Quest's largest region, where she drove market expansion and operational efficiencies. Before Quest, Ms. Kama established an impressive track record of transformative and growth-oriented leadership across a diverse range of multibillion-dollar organizations, including FedEx, United Airlines, A&P, and AIG, where she held senior leadership roles in strategic planning, financial planning and analysis, capital planning and corporate strategy.

    "I am pleased to welcome Gülsen to Bionano. We believe the combination of her track record managing financial strategy at global businesses, including Quest Diagnostics and United Airlines, combined with her experience helping scale startup Northern Data, make her well-suited to help Bionano continue transforming cytogenetics into a streamlined workflow in healthcare while charting a course toward profitability. Gülsen has decades of capital management experience at complex companies, where she helped improve efficiency and implemented cost controls, resulting in higher returns to shareholders. All of us on the senior leadership team are really looking forward to partnering with Gülsen as she helps propel us to reach new heights. We also extend our gratitude to Chris Stewart for his leadership in helping us transition out of the pandemic and build our growing business," commented Erik Holmlin, PhD, president and chief executive officer of Bionano.

    About Bionano

    Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company's mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. The Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. The Company additionally offers nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. For more information, visit www.bionano.com, www.bionanolaboratories.com or www.purigenbio.com.

    Bionano's OGM products are for research use only and not for use in diagnostic procedures.

    Forward-Looking Statements of Bionano

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believe," "plan," "potential," "will" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations, including any potential benefits that may be realized as a result of new members of management. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of geopolitical and macroeconomic developments, such as recent and potential future bank failures, the ongoing Ukraine-Russian conflict, and related sanctions, and any global pandemics, on our business and the global economy; execution of our stated strategies and plans[delete extra space]; general market conditions; changes in the competitive landscape and the introduction of competitive technologies or improvements to existing technologies; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts and our ability to continue as a "going concern"; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2022 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

    CONTACTS

    Company Contact:

    Erik Holmlin, CEO

    Bionano Genomics, Inc.

    +1 (858) 888-7610

    [email protected]

    Investor Relations:

    David Holmes

    Gilmartin Group

    +1 (858) 888-7625

    [email protected]





    Primary Logo

    Get the next $BNGO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BNGO

    DatePrice TargetRatingAnalyst
    11/15/2024Buy → Neutral
    Ladenburg Thalmann
    9/10/2024Buy → Neutral
    BTIG Research
    1/5/2023$4.00Sector Outperform
    Scotiabank
    12/12/2022$3.50Buy
    BTIG Research
    7/18/2022$12.00Outperform
    Oppenheimer
    More analyst ratings

    $BNGO
    Financials

    Live finance-specific insights

    See more
    • Bionano to Report First Quarter 2025 Financial Results and Host a Conference Call Webcast on May 14, 2025

      SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Wednesday, May 14, 2025, at 4:30 p.m. Eastern Time to report financial results for the first quarter 2025 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Wednesday, May 14th, 2025Time:4:30 p.m. ETParticipant Link:Registration – Click hereWebcast Link:https://edge.media-server.com/mmc/p/vncjmqc9 Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano's investor relations website at https://ir.b

      5/7/25 4:01:00 PM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bionano to Report Fourth Quarter and Full Year 2024 Financial Results and Host a Conference Call Webcast on March 31, 2025

      SAN DIEGO, March 14, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Monday, March 31, 2025, at 4:30 p.m. Eastern Time to report financial results for the fourth quarter and full year 2024 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Monday, March 31st, 2025Time:4:30 p.m. ETParticipant Link:Registration – Click HereWebcast Link:https://edge.media-server.com/mmc/p/5v2s5x5r Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano's investor relations website

      3/14/25 8:00:00 AM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bionano to Report Third Quarter 2024 Financial Results and Host a Conference Call and Webcast on November 13, 2024

      SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Wednesday, November 13, 2024, at 4:30 p.m. Eastern Time to report financial results for the third quarter 2024 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Wednesday, November 13th, 2024Time:4:30 p.m. ETParticipant Link:Registration – Click HereWebcast Link:https://edge.media-server.com/mmc/p/dmabxin9 Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano's investor relations website at h

      11/7/24 4:01:00 PM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BNGO
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Bionano Genomics Inc.

      DEFA14A - Bionano Genomics, Inc. (0001411690) (Filer)

      4/28/25 4:17:17 PM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form DEF 14A filed by Bionano Genomics Inc.

      DEF 14A - Bionano Genomics, Inc. (0001411690) (Filer)

      4/28/25 4:15:40 PM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form PRE 14A filed by Bionano Genomics Inc.

      PRE 14A - Bionano Genomics, Inc. (0001411690) (Filer)

      4/18/25 4:15:28 PM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BNGO
    Leadership Updates

    Live Leadership Updates

    See more
    • LeddarTech Appoints Chris Stewart as Chief Financial Officer

      QUEBEC CITY, Canada, Nov. 15, 2023 (GLOBE NEWSWIRE) -- LeddarTech®, an automotive software company that provides patented disruptive low-level sensor fusion and perception software technology for ADAS and AD, proudly announces the appointment of Mr. Chris Stewart as Chief Financial Officer ("CFO"). As CFO at LeddarTech, Mr. Stewart will be instrumental in supporting LeddarTech in completing its recently announced business combination with Prospector Capital Corp. and transitioning to a publicly traded company. Mr. Stewart has over 20 years of financial management experience at companies ranging from startups to large public companies. Mr. Stewart previously served as the Chief Financial

      11/15/23 12:07:00 AM ET
      $BNGO
      $PRSR
      $TSLA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Blank Checks
      Finance
    • Bionano Announces CFO Transition and Appointment of Gülsen Kama as Chief Financial Officer

      SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that Gülsen Kama will serve as its next Chief Financial Officer (CFO), effective September 11, 2023. Christopher Stewart, who held the position of CFO since September 2020, will stay on during the transition and then move into an advisory role. Ms. Kama has an extensive background in business planning and execution, especially in operating environments that demand rigorous management of expenses to enable profitable growth. She was most recently Chief Financial Officer at Northern Data AG, where she created and implemented a global finance organization to enable strong growth. Prior to Northe

      8/14/23 8:00:00 AM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bionano Genomics Appoints Donna Polizio as Its First Ever Global Head of Market Access

      SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it has appointed Donna Polizio as its global head of market access, further strengthening its leadership team. The appointment of a global head of market access reflects Bionano's focus on advancing the adoption of optical genome mapping (OGM) and working to meet market needs. Ms. Polizio was most recently the vice president of U.S. managed care and reimbursement at Genomic Health, acquired by Exact Sciences in 2019. In this role, she managed payor contracting and reimbursements that helped drive profitability of Genomic Health prior to its acquisition. Ms. Polizio has also held senior l

      11/10/22 8:00:00 AM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BNGO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bionano to Report First Quarter 2025 Financial Results and Host a Conference Call Webcast on May 14, 2025

      SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Wednesday, May 14, 2025, at 4:30 p.m. Eastern Time to report financial results for the first quarter 2025 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Wednesday, May 14th, 2025Time:4:30 p.m. ETParticipant Link:Registration – Click hereWebcast Link:https://edge.media-server.com/mmc/p/vncjmqc9 Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano's investor relations website at https://ir.b

      5/7/25 4:01:00 PM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • International Consortium for Optical Genome Mapping Publishes Expert Recommendations for Integration of OGM as a Standard-of-Care Cytogenetic Assay for Diagnostic Workflows in Blood Cancers

      SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (NASDAQ:BNGO) that offers CLIA-certified laboratory developed tests (LDTs) based on optical genome mapping (OGM), today announced the publication in the American Journal of Hematology of expert recommendations from the International Consortium for Optical Genome Mapping (ICOGM) for the integration of OGM as a standard-of-care (SOC) cytogenetic assay for diagnostic workflows in various clinical settings. Nineteen (19) experts from the ICOGM, representing relevant multidisciplinary fields, conducted an in-depth review of the classification of hematolymphoid malignancies usin

      5/2/25 9:30:12 AM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bionano Announces Publication Showing OGM can Provide an Accurate and Cost-Effective Solution for Sizing Large Repeat Expansions in Constitutional Genetic Disease

      SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced a peer-reviewed publication in Genome Research demonstrating that optical genome Mapping (OGM) can be an accurate, cost-effective method for detecting and sizing large repeat expansions, which are a class of structural variation (SV) linked to as many as 40 genetic disorders. Led by Alexander Hoischen and researchers at Radboud University Medical Center in the Netherlands, the study provides one of the most comprehensive evaluations to date of OGM as a single workflow for characterizing large repeat expansions. Researchers evaluated 85 subjects containing known pathogenic expansions in three

      4/23/25 8:00:00 AM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BNGO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Bionano Genomics Inc. (Amendment)

      SC 13G/A - Bionano Genomics, Inc. (0001411690) (Subject)

      2/13/24 5:00:51 PM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Bionano Genomics Inc. (Amendment)

      SC 13G/A - Bionano Genomics, Inc. (0001411690) (Subject)

      7/7/23 4:35:55 PM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Bionano Genomics Inc. (Amendment)

      SC 13G/A - Bionano Genomics, Inc. (0001411690) (Subject)

      1/30/23 4:03:23 PM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BNGO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $BNGO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SEC Form 4 filed by General Counsel Dixon Jonathan V.

      4 - Bionano Genomics, Inc. (0001411690) (Issuer)

      3/18/25 6:45:55 PM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 4 filed by Principal Accounting Officer Adamchak Mark

      4 - Bionano Genomics, Inc. (0001411690) (Issuer)

      3/18/25 6:45:45 PM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • President and CEO Holmlin R. Erik covered exercise/tax liability with 198 shares, decreasing direct ownership by 10% to 1,783 units (SEC Form 4)

      4 - Bionano Genomics, Inc. (0001411690) (Issuer)

      3/18/25 6:45:35 PM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bionano Genomics downgraded by Ladenburg Thalmann

      Ladenburg Thalmann downgraded Bionano Genomics from Buy to Neutral

      11/15/24 7:40:01 AM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bionano Genomics downgraded by BTIG Research

      BTIG Research downgraded Bionano Genomics from Buy to Neutral

      9/10/24 7:37:53 AM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Scotiabank initiated coverage on Bionano Genomics with a new price target

      Scotiabank initiated coverage of Bionano Genomics with a rating of Sector Outperform and set a new price target of $4.00

      1/5/23 7:29:54 AM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials